Signals, Powered By EquityPandit
Suven Life Science has got one product patent from New Zealand for its molecule to be used in treating neuro-degenerative diseases.
Suven Life Science has said in a BSE filing that with this new patent, Suven has a total of 26 patents from New Zealand. The new patent is valid through 2033.
Suven CEO Venkat Jasti has said that “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
